Implementing agile solutions to successfully deliver a vaccine clinical trial in China
Related insights
More from our insights
![Navigating a dynamic study design in hepatitis B research](https://www.fortrea.com/sites/default/files/2025-02/navigating-dynamic-study-design-in-hepatitis-b-research.jpg)
Navigating a dynamic study design in hepatitis B research
A major pharmaceutical company partnered with Fortrea for a Phase II platform study. The trial's dynamic study design allowed for the addition and removal of study drugs in various treatment arms and combinations.
Descargar estudio de casos![Key challenges in pediatric vaccine trials in low- and middle- income countries](https://www.fortrea.com/sites/default/files/2025-01/key-challenges-in-pediatric-vaccines.jpg)
Key challenges in pediatric vaccine trials in low- and middle- income countries
Low- and middle-income countries (LMICs) bear a disproportionate burden of infectious diseases, with 90% of preventable cases occurring in these regions.
Leer más![See how we navigated complexities in a Phase I ICU trial](https://www.fortrea.com/sites/default/files/2025-01/see-how-we-navigated-complexities-in-a-phase-I-icu-trial.jpg)
See how we navigated complexities in a Phase I ICU trial
Recent years have seen a growing need for advanced critical care solutions, driven by factors such as an aging population, emerging infectious diseases and increasingly complex medical interventions.
Leer más![Rapid diagnostic advantages in clinical research](https://www.fortrea.com/sites/default/files/2025-01/rapid-diagnostic-advantages-in-clinical-research.jpg)
Rapid diagnostic advantages in clinical research
The COVID-19 pandemic demonstrated how lateral flow point-of-care (POC) testing can improve target population enrichment and decrease loss of patients to key analysis sets once confirmatory testing becomes available.
Leer más![Leveraging Technology for Vaccine Trial Surveillance](https://www.fortrea.com/sites/default/files/2025-01/leveraging-technology-for-vaccine-trial-surveillance%E2%80%AF.jpg)
Leveraging Technology for Vaccine Trial Surveillance
Vaccine trial sponsors face mounting pressure to accelerate development timelines while upholding the highest standards of data quality and participant safety.
Leer más![Streamlining Site Selection and Participant Compliance for Vaccine Trials](https://www.fortrea.com/sites/default/files/2025-01/optimizing-vaccine-trials-for-sites-and-participants-banner.jpg)
Streamlining Site Selection and Participant Compliance for Vaccine Trials
Two critical factors can make or break a large-scale vaccine trial: site selection and participant compliance.
Leer más![Agility in Action: The Key to Successful Large-Scale Vaccine Trials](https://www.fortrea.com/sites/default/files/2025-01/agility-in-action-fortrea-banner.jpg)
Agility in Action: The Key to Successful Large-Scale Vaccine Trials
Sponsors face immense pressure to deliver safe and effective vaccines quickly.
Leer más![](https://www.fortrea.com/sites/default/files/2024-11/GettyImages-1162117373%20%281%29.webp)
Creative problem-solving supports site recruitment in a complex sepsis study
Descargar estudio de casos![](https://www.fortrea.com/sites/default/files/2024-11/GettyImages-908538186%20%281%29.webp)
Implementing a novel approach for recruiting a seasonal pediatric vaccine mega-trial
This case study demonstrates how Fortrea developed a novel approach to successfully delivery a large, industry-sponsored Phase III clinical trial to prevent hospitalization of infants due to a seasonal and dangerous illness.
Descargar estudio de casos![](https://www.fortrea.com/sites/default/files/2024-10/GettyImages-485488627.webp)
Creating patient- and site-centric solutions for a challenging antibiotic study
A pharmaceutical company partnered with Fortrea to support their Phase 1b pharmacokinetic clinical trial of a new antibiotic candidate for life-threatening nosocomial infections, including drug-resistant infections.
Descargar estudio de casosContáctenos
We've been driving innovation with our tailored clinical solutions for 30+ years. Let's connect.